Cellid, Co., Ltd. (KOSDAQ:299660)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,330.00
-80.00 (-2.35%)
At close: Dec 5, 2025
-47.14%
Market Cap 98.24B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 29.50M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 387,122
Average Volume 462,025
Open 3,410.00
Previous Close 3,410.00
Day's Range 3,255.00 - 3,470.00
52-Week Range 3,035.00 - 9,910.00
Beta 1.57
RSI 45.86
Earnings Date n/a

About Cellid,

Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2006
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 299660
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.